1	Novel	Novel	B-NP	JJ	O	3	NMOD	-1
2	biological	biological	I-NP	JJ	O	3	NMOD	-1
3	agents	agent	I-NP	NNS	O	0	ROOT	-1
4	for	for	B-PP	IN	O	3	NMOD	-1
5	the	the	B-NP	DT	O	6	NMOD	-1
6	treatment	treatment	I-NP	NN	O	4	PMOD	19	treatment
7	of	of	B-PP	IN	O	6	NMOD	-1
8	hormone-refractory	hormone-refractory	B-NP	JJ	O	10	NMOD	-1
9	prostate	prostate	I-NP	NN	O	10	NMOD	-1
10	cancer	cancer	I-NP	NN	O	7	PMOD	-1
11	(	(	O	(	O	13	DEP	-1
12	HRPC	HRPC	B-NP	NN	B-protein	13	DEP	-1
13	)	)	O	)	O	10	NMOD	-1
14	.	.	O	.	O	3	P	-1

1	Hormone-refractory	Hormone-refractory	B-NP	JJ	O	3	NMOD	-1
2	prostate	prostate	I-NP	NN	O	3	NMOD	-1
3	cancer	cancer	I-NP	NN	O	7	SUB	-1
4	(	(	O	(	O	6	DEP	-1
5	HRPC	HRPC	B-NP	NN	B-protein	6	DEP	-1
6	)	)	O	)	O	3	NMOD	-1
7	is	be	B-VP	VBZ	O	0	ROOT	-1
8	an	an	B-NP	DT	O	10	NMOD	-1
9	inevitable	inevitable	I-NP	JJ	O	10	NMOD	-1
10	evolution	evolution	I-NP	NN	O	7	PRD	-1
11	of	of	B-PP	IN	O	10	NMOD	-1
12	prostate	prostate	B-NP	NN	O	13	NMOD	-1
13	carcinogenesis	carcinogenesis	I-NP	NN	O	11	PMOD	2	carcinogenesis
14	,	,	O	,	O	7	P	-1
15	through	through	B-PP	IN	O	7	VMOD	0
16	which	which	B-NP	WDT	O	15	PMOD	-1
17	the	the	B-NP	DT	O	19	NMOD	-1
18	normal	normal	I-NP	JJ	O	19	NMOD	-1
19	dependence	dependence	I-NP	NN	O	26	SUB	-1
20	on	on	B-PP	IN	O	19	NMOD	-1
21	hormones	hormone	B-NP	NNS	O	20	PMOD	-1
22	for	for	B-PP	IN	O	21	NMOD	-1
23	growth	growth	B-NP	NN	O	25	NMOD	0
24	and	and	I-NP	CC	O	25	NMOD	-1
25	survival	survival	I-NP	NN	O	22	PMOD	0
26	is	be	B-VP	VBZ	O	15	SBAR	-1
27	bypassed	bypass	I-VP	VBN	O	26	VC	-1
28	.	.	O	.	O	7	P	-1

1	Although	Although	B-SBAR	IN	O	23	VMOD	-1
2	advances	advance	B-NP	NNS	O	13	SUB	-1
3	in	in	B-PP	IN	O	2	NMOD	-1
4	terms	term	B-NP	NNS	O	3	PMOD	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	symptoms	symptom	B-NP	NNS	O	9	NMOD	-1
7	palliation	palliation	I-NP	NN	O	9	NMOD	-1
8	and	and	O	CC	O	9	NMOD	-1
9	quality	quality	B-NP	NN	O	5	PMOD	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	life	life	B-NP	NN	O	12	NMOD	-1
12	improvement	improvement	I-NP	NN	O	10	PMOD	-1
13	have	have	B-VP	VBP	O	1	SBAR	-1
14	been	be	I-VP	VBN	O	13	VC	-1
15	addressed	address	I-VP	VBN	O	14	VC	-1
16	with	with	B-PP	IN	O	15	VMOD	-1
17	current	current	B-NP	JJ	O	19	NMOD	-1
18	treatment	treatment	I-NP	NN	O	19	NMOD	0
19	options	option	I-NP	NNS	O	16	PMOD	-1
20	,	,	O	,	O	23	P	-1
21	innovative	innovative	B-NP	JJ	O	22	NMOD	-1
22	approaches	approach	I-NP	NNS	O	23	SUB	-1
23	are	be	B-VP	VBP	O	0	ROOT	-1
24	needed	need	I-VP	VBN	O	23	VC	-1
25	to	to	B-VP	TO	O	26	VMOD	-1
26	improve	improve	I-VP	VB	O	24	VMOD	0
27	survival	survival	B-NP	NN	O	28	NMOD	0
28	rates	rate	I-NP	NNS	O	26	OBJ	-1
29	.	.	O	.	O	23	P	-1

1	A	A	B-NP	DT	O	3	NMOD	-1
2	thorough	thorough	I-NP	JJ	O	3	NMOD	-1
3	understanding	understanding	I-NP	NN	O	0	ROOT	-1
4	of	of	B-PP	IN	O	3	NMOD	-1
5	HRPC-associated	HRPC-associated	B-NP	JJ	O	7	NMOD	-1
6	molecular	molecular	I-NP	JJ	O	7	NMOD	-1
7	pathways	pathway	I-NP	NNS	O	4	PMOD	0
8	and	and	I-NP	CC	O	9	NMOD	-1
9	mechanisms	mechanism	I-NP	NNS	O	12	SUB	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	resistance	resistance	B-NP	NN	O	10	PMOD	-1
12	are	be	B-VP	VBP	O	7	NMOD	-1
13	a	a	B-NP	DT	O	14	NMOD	-1
14	prerequisite	prerequisite	I-NP	NN	O	12	PRD	-1
15	for	for	B-PP	IN	O	14	NMOD	-1
16	novel	novel	B-NP	JJ	O	18	AMOD	-1
17	potential	potential	I-NP	JJ	O	18	AMOD	0
18	therapeutic	therapeutic	I-NP	JJ	O	19	NMOD	-1
19	interventions	intervention	I-NP	NNS	O	15	PMOD	0
20	.	.	O	.	O	3	P	-1

1	Preclinical	Preclinical	B-NP	JJ	O	5	NMOD	-1
2	and	and	I-NP	CC	O	5	NMOD	-1
3	early	early	I-NP	JJ	O	5	NMOD	-1
4	clinical	clinical	I-NP	JJ	O	5	NMOD	-1
5	studies	study	I-NP	NNS	O	6	SUB	-1
6	are	be	B-VP	VBP	O	0	ROOT	-1
7	ongoing	ongoe	I-VP	VBG	O	6	VC	-1
8	to	to	I-VP	TO	O	9	VMOD	-1
9	evaluate	evaluate	I-VP	VB	O	7	VMOD	-1
10	new	new	B-NP	JJ	O	11	NMOD	-1
11	therapies	therapy	I-NP	NNS	O	9	OBJ	0
12	that	that	B-NP	WDT	O	11	NMOD	-1
13	target	target	B-VP	VBP	O	12	SBAR	0
14	specific	specific	B-NP	JJ	O	16	NMOD	-1
15	molecular	molecular	I-NP	JJ	O	16	NMOD	-1
16	entities	entity	I-NP	NNS	O	13	OBJ	-1
17	.	.	O	.	O	6	P	-1

1	Agents	Agent	B-NP	NNS	O	4	SUB	-1
2	under	under	B-PP	IN	O	1	NMOD	-1
3	development	development	B-NP	NN	O	2	PMOD	0
4	include	include	B-VP	VBP	O	0	ROOT	-1
5	growth	growth	B-NP	NN	B-protein	8	NMOD	0
6	factor	factor	I-NP	NN	I-protein	8	NMOD	-1
7	receptor	receptor	I-NP	NN	I-protein	8	NMOD	-1
8	inhibitors	inhibitor	I-NP	NNS	O	35	NMOD	-1
9	,	,	O	,	O	35	P	-1
10	small	small	B-NP	JJ	O	11	NMOD	-1
11	molecules	molecule	I-NP	NNS	O	35	NMOD	-1
12	targeting	target	B-VP	VBG	O	11	NMOD	0
13	signal	signal	B-NP	NN	O	15	NMOD	-1
14	transduction	transduction	I-NP	NN	O	15	NMOD	-1
15	pathways	pathway	I-NP	NNS	O	12	OBJ	0
16	,	,	O	,	O	35	P	-1
17	apoptosis	apoptosis	B-NP	NN	O	20	NMOD	0
18	and	and	O	CC	O	20	NMOD	-1
19	cell-cycle	cell-cycle	B-NP	JJ	B-protein	20	NMOD	-1
20	regulators	regulator	I-NP	NNS	I-protein	35	NMOD	-1
21	,	,	O	,	O	35	P	-1
22	angiogenesis	angiogenesis	B-NP	NN	O	25	NMOD	3	angiogenesis
23	and	and	I-NP	CC	O	25	NMOD	-1
24	metastasis	metastasis	I-NP	NN	O	25	NMOD	0
25	inhibitors	inhibitor	I-NP	NNS	O	35	NMOD	-1
26	,	,	O	,	O	35	P	-1
27	differentiation	differentiation	B-NP	NN	O	28	NMOD	0
28	agents	agent	I-NP	NNS	O	35	NMOD	-1
29	,	,	O	,	O	35	P	-1
30	telomerase	telomerase	B-NP	NN	B-protein	31	NMOD	-1
31	inactivators	inactivator	I-NP	NNS	I-protein	35	NMOD	-1
32	,	,	O	,	O	35	P	-1
33	and	and	O	CC	O	35	NMOD	-1
34	epigenetic	epigenetic	B-NP	JJ	O	35	NMOD	-1
35	therapeutics	therapeutic	I-NP	NNS	O	4	OBJ	-1
36	.	.	O	.	O	4	P	-1

1	Incorporation	Incorporation	B-NP	NN	O	9	SUB	0
2	of	of	B-PP	IN	O	1	NMOD	-1
3	these	these	B-NP	DT	O	4	NMOD	-1
4	agents	agent	I-NP	NNS	O	2	PMOD	-1
5	into	into	B-PP	IN	O	1	NMOD	-1
6	existing	exist	B-NP	VBG	O	8	NMOD	-1
7	treatment	treatment	I-NP	NN	O	8	NMOD	0
8	regimens	regimen	I-NP	NNS	O	5	PMOD	-1
9	will	will	B-VP	MD	O	0	ROOT	-1
10	guide	guide	I-VP	VB	O	9	VC	-1
11	us	us	B-NP	PRP	O	10	OBJ	-1
12	in	in	B-PP	IN	O	10	VMOD	-1
13	the	the	B-NP	DT	O	14	NMOD	-1
14	development	development	I-NP	NN	O	12	PMOD	0
15	of	of	B-PP	IN	O	14	NMOD	-1
16	a	a	B-NP	DT	O	19	NMOD	-1
17	multidisciplinary	multidisciplinary	I-NP	JJ	O	19	NMOD	-1
18	treatment	treatment	I-NP	NN	O	19	NMOD	0
19	strategy	strategy	I-NP	NN	O	15	PMOD	-1
20	of	of	B-PP	IN	O	19	NMOD	-1
21	HRPC	HRPC	B-NP	NN	B-cell_type	20	PMOD	-1
22	.	.	O	.	O	9	P	-1

1	This	This	B-NP	DT	O	2	NMOD	-1
2	article	article	I-NP	NN	O	4	SUB	-1
3	critically	critically	B-ADVP	RB	O	4	VMOD	-1
4	reviews	review	B-VP	VBZ	O	0	ROOT	-1
5	published	publish	I-VP	VBN	O	6	NMOD	-1
6	data	datum	B-NP	NNS	O	4	OBJ	-1
7	on	on	B-PP	IN	O	6	NMOD	-1
8	new	new	B-NP	JJ	O	10	NMOD	-1
9	biological	biological	I-NP	JJ	O	10	NMOD	-1
10	agents	agent	I-NP	NNS	O	7	PMOD	-1
11	that	that	B-NP	WDT	O	10	NMOD	-1
12	are	be	B-VP	VBP	O	11	SBAR	-1
13	being	be	I-VP	VBG	O	12	VC	-1
14	tested	test	I-VP	VBN	O	13	VC	-1
15	in	in	B-PP	IN	O	14	VMOD	-1
16	HRPC	HRPC	B-NP	NN	B-cell_type	18	NMOD	-1
17	clinical	clinical	B-NP	JJ	O	18	NMOD	-1
18	trials	trial	I-NP	NNS	O	15	PMOD	-1
19	,	,	O	,	O	4	P	-1
20	highlights	highlight	B-VP	VBZ	O	4	VMOD	-1
21	ongoing	ongoing	B-NP	JJ	O	22	NMOD	-1
22	research	research	I-NP	NN	O	20	OBJ	-1
23	and	and	O	CC	O	4	VMOD	-1
24	considers	consider	B-VP	VBZ	O	4	VMOD	-1
25	the	the	B-NP	DT	O	27	NMOD	-1
26	future	future	I-NP	JJ	O	27	NMOD	-1
27	perspectives	perspective	I-NP	NNS	O	24	OBJ	-1
28	of	of	B-PP	IN	O	27	NMOD	-1
29	this	this	B-NP	DT	O	31	NMOD	-1
30	new	new	I-NP	JJ	O	31	NMOD	-1
31	class	class	I-NP	NN	O	28	PMOD	-1
32	of	of	B-PP	IN	O	31	NMOD	-1
33	agents	agent	B-NP	NNS	O	32	PMOD	-1
34	.	.	O	.	O	4	P	-1

